Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmanex red yeast "mutant" strain patent shows intent to enhance lovastatin -- Merck.

This article was originally published in The Tan Sheet

Executive Summary

PHARMANEX RED YEAST RICE PATENT APPLICATION DESCRIBING "MUTANT" STRAIN demonstrates the company's Cholestin dietary supplement is made of traditional red yeast rice that has been manipulated to ensure a substantial lovastatin content, Merck argues in May 5 comments to FDA. An international patent application filed by Pharmanex and Peking University Sept. 29 "makes clear that Cholestin is not traditional red yeast rice, or Hong Qu, and that the process for producing Cholestin has been modified to produce a new product enhanced for production of ingredients that lower cholesterol," Merck maintains.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088425

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel